Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Haemonetics Corp (HAE)

Haemonetics Corp (HAE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,903,409
  • Shares Outstanding, K 50,224
  • Annual Sales, $ 1,309 M
  • Annual Income, $ 117,560 K
  • EBIT $ 207 M
  • EBITDA $ 311 M
  • 60-Month Beta 0.41
  • Price/Sales 3.02
  • Price/Cash Flow 13.02
  • Price/Book 4.59

Options Overview Details

View History
  • Implied Volatility 42.49% ( +2.00%)
  • Historical Volatility 28.35%
  • IV Percentile 80%
  • IV Rank 54.32%
  • IV High 57.61% on 11/06/24
  • IV Low 24.51% on 08/26/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 100
  • Volume Avg (30-Day) 1,214
  • Put/Call OI Ratio 1.10
  • Today's Open Interest 10,912
  • Open Int (30-Day) 12,053

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.19
  • Number of Estimates 5
  • High Estimate 1.21
  • Low Estimate 1.17
  • Prior Year 1.04
  • Growth Rate Est. (year over year) +14.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
74.49 +4.85%
on 12/23/24
85.00 -8.12%
on 12/10/24
-3.09 (-3.81%)
since 12/06/24
3-Month
70.25 +11.17%
on 10/31/24
94.99 -17.78%
on 11/12/24
+1.42 (+1.85%)
since 10/08/24
52-Week
70.25 +11.17%
on 10/31/24
97.97 -20.28%
on 05/15/24
-7.08 (-8.31%)
since 01/08/24

Most Recent Stories

More News
Should National Vision Stock Be in Your Portfolio Right Now?

National Vision Holdings, Inc. EYE is winning market shares across four sub segments of the Owned and Host. The company is also advancing its transformation efforts with continued expansion of exam capacity,...

VCYT : 43.78 (+3.04%)
EYE : 10.54 (-3.30%)
PAHC : 21.48 (+3.87%)
HAE : 78.10 (+0.49%)
Macroeconomic Woes, FX Headwind Drag NEOG Stock Down

Neogen's NEOG vast international trade is being impacted by global macroeconomic issues. Also, a tough competitive landscape weighs on the stock. NEOG stock carries a Zacks Rank #4 (Sell) currently.Factors...

VCYT : 43.78 (+3.04%)
PAHC : 21.48 (+3.87%)
NEOG : 13.07 (+0.69%)
HAE : 78.10 (+0.49%)
Henry Schein Stock to Gain From New Acquisitions Amid Macro Woes

Henry Schein HSIC is well positioned to gain from its extensive global foothold and diverse channel mix.  Yet, global economic uncertainties are concerns for Henry Schein. The stock carries a Zacks Rank...

VCYT : 43.78 (+3.04%)
HSIC : 71.06 (-0.85%)
PAHC : 21.48 (+3.87%)
HAE : 78.10 (+0.49%)
Bruker Adds Another 1.2 GHz NMR System in Switzerland, Stock Climbs

Bruker Corporation’s BRKR 1.2 GHz Ascend Nuclear Magnetic Resonance (NMR) spectrometer has been accepted at the Swiss High-field NMR Facility, operated jointly by the University of Basel, ETH Zürich,...

BRKR : 60.95 (-0.49%)
PEN : 257.81 (+2.21%)
PAHC : 21.48 (+3.87%)
HAE : 78.10 (+0.49%)
MYGN Stock Might Gain From the New Recognition of RiskScore Study

Myriad Genetics, Inc.’s MYGN MyRisk Hereditary Cancer Test with RiskScore study has been named as one of its top 10 significant advances in genomic medicine by the American Journal of Human Genetics....

MYGN : 14.78 (+3.36%)
PEN : 257.81 (+2.21%)
PAHC : 21.48 (+3.87%)
HAE : 78.10 (+0.49%)
Teleflex Expands CVC Portfolio in EMEA With New Launch: Stock to Gain?

Teleflex TFX recently launched its new Pressure Injectable Arrowg+ard Blue Plus MSB Procedure Kit in Europe, the Middle East and Africa (EMEA). This is regarded as a significant addition to the company’s...

TFX : 177.96 (-1.02%)
PEN : 257.81 (+2.21%)
PAHC : 21.48 (+3.87%)
HAE : 78.10 (+0.49%)
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain?

Myriad Genetics, Inc.’s MYGN Prolaris prostate cancer prognostic test has been reinforced as an ‘Advanced Tool’ by the National Comprehensive Cancer Network (“NCCN”) in the fight against prostate...

MYGN : 14.78 (+3.36%)
PEN : 257.81 (+2.21%)
PAHC : 21.48 (+3.87%)
HAE : 78.10 (+0.49%)
CRL Stock to Gain From the Global Biotech Incubator Program Launch

Charles River Laboratories International, Inc. CRL has launched the Charles River Incubator Program (“CIP”) via its Global Innovation Center of Excellence (CoE). The initiative is designed to support...

PEN : 257.81 (+2.21%)
PAHC : 21.48 (+3.87%)
CRL : 187.91 (-0.97%)
HAE : 78.10 (+0.49%)
Haemonetics: Fiscal Q2 Earnings Snapshot

Haemonetics: Fiscal Q2 Earnings Snapshot

HAE : 78.10 (+0.49%)
Haemonetics: Fiscal Q1 Earnings Snapshot

Haemonetics: Fiscal Q1 Earnings Snapshot

HAE : 78.10 (+0.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Haemonetics Corp. provides blood management solutions to customers encompassing blood and plasma collectors, hospitals and health care providers globally. Its portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood...

See More

Key Turning Points

3rd Resistance Point 80.83
2nd Resistance Point 79.55
1st Resistance Point 78.83
Last Price 78.10
1st Support Level 76.82
2nd Support Level 75.54
3rd Support Level 74.82

See More

52-Week High 97.97
Fibonacci 61.8% 87.38
Fibonacci 50% 84.11
Fibonacci 38.2% 80.84
Last Price 78.10
52-Week Low 70.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar